The Department of Defense has issued a notice advising interested parties of a demonstration project in which the department will evaluate allowing selected OTCs to be included on the TRICARE uniform formulary.
The Department of Defense has issued a notice advising interested parties of a demonstration project in which the department will evaluate allowing selected OTCs to be included on the TRICARE uniform formulary. The demonstration project will be available for beneficiaries within the U.S., Puerto Rico, the Virgin Islands, and Guam. The notice appeared in the June 15 Federal Register. For more information, call (703) 681-2890.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.